Atrial fibrillation ECG recognition: the three hallmarks
Atrial fibrillation has three defining ECG features that together make it one of the most recognizable arrhythmias:
1. Irregularly irregular R-R intervals: no two consecutive R-R intervals are equal, and there is no predictable pattern. This is the most clinically important feature — it distinguishes AFib from all regularly irregular rhythms (Wenckebach, bigeminy) and all regular tachycardias (SVT, sinus tach). Even brief periods of regularity within AFib should prompt reconsideration of the diagnosis.
2. Absent organized P waves: instead of discrete P waves, the baseline between QRS complexes shows fine fibrillatory activity — low-amplitude, rapid (350–600/min), irregular oscillations. This represents chaotic atrial electrical activity from multiple simultaneous re-entrant wavelets. In coarse AFib, these fibrillatory waves are more prominent; in fine AFib, the baseline may appear nearly flat.
3. Narrow QRS (unless aberrancy): ventricular conduction remains normal via the His-Purkinje system, producing a narrow QRS. A wide QRS in AFib indicates either pre-existing bundle branch block, rate-related aberrancy (Ashman phenomenon), or pre-excitation via an accessory pathway (AFib + WPW — a dangerous combination requiring different management).
AFib nursing priorities: rate, rhythm, and anticoagulation
Hemodynamic assessment first: Is the patient hemodynamically stable (adequate BP, no altered mentation, no pulmonary edema)? Unstable → synchronized cardioversion. Stable → pharmacologic rate or rhythm control.
Rate control target: resting ventricular rate < 80–110 bpm. IV metoprolol (contraindicated in HFrEF) or diltiazem (contraindicated in preexcitation). Amiodarone for rate control in hemodynamically compromised patients.
Duration assessment determines anticoagulation approach: onset < 48 hours — lower thrombus risk, cardioversion without prolonged anticoagulation may be safe. Onset unknown or > 48 hours — anticoagulate for ≥ 3 weeks before elective cardioversion, OR perform TEE to rule out LAA thrombus. Post-cardioversion: anticoagulate for ≥ 4 weeks regardless of duration.
CHA₂DS₂-VASc score drives long-term anticoagulation decision: ≥ 2 in men or ≥ 3 in women = anticoagulation indicated (DOACs preferred over warfarin unless mechanical valve or CrCl < 15 mL/min).